Overview of Rowasa

Property	Description
Active Ingredient	Mesalamine (5-aminosalicylic acid, 5-ASA)
Forms	Rectal suspension (enema), suppository
Pharmacological Class	Aminosalicylate anti-inflammatory agent
Common Therapeutic Role	Localized anti-inflammatory therapy
Origin	Synthetic chemical compound

Rowasa: Classification and Active Component

Rowasa is a prescription-only medication whose active compound is Mesalamine, a synthetic substance also identified as 5-aminosalicylic acid (5-ASA). It is designated as an Aminosalicylate, a pharmacological class of anti-inflammatory agents widely clinically recognized for its role in managing intestinal inflammation. The classification establishes its primary function as an agent that modifies the inflammatory process at the tissue level.

Pharmaceutical Form and Site-Specific Delivery

Rowasa is uniquely formulated for rectal administration, supplied as a rectal suspension (enema) and, in some cases, a suppository. This composition is a single-ingredient product designed to facilitate the delivery of Mesalamine directly to the lining of the rectum and lower colon. This strategic approach ensures that a concentrated amount of the active compound reaches the affected area, maximizing its local therapeutic effect. The specialized rectal formulation provides site-specific therapy with limited distribution throughout the rest of the body.

General Therapeutic Role and Anti-Inflammatory Purpose

The primary therapeutic role of Rowasa is to provide potent, localized anti-inflammatory therapy within the distal bowel. Mesalamine works through a localized action, mitigating inflammation by reducing the production of specific chemical messengers, such as prostaglandins, that drive the inflammatory response in the intestinal wall. This anti-inflammatory mechanism is consistently supported by pharmacological studies, which highlight its specific ability to suppress the inflammatory cascade in the gastrointestinal mucosa. This targeted approach makes it a recognized therapeutic option for cooling down tissue inflammation.

Regulatory References

Mesalamine (USAN) - StatPearls - NCBI Bookshelf

What side effects are possible with Rowasa?

Possible Side Effects and Safety Information

Rowasa (mesalamine rectal formulations) has an official safety profile structured around classified adverse reactions and specific systemic safety considerations documented by regulatory authorities. The adverse effects are typically categorized by frequency and the body system affected, consistent with regulatory guidelines.

Adverse Reactions Classified by Frequency

Side effects documented as Common (reported in 1% of patients in trials) include headache, flatulence, abdominal pain or discomfort, nausea, diarrhea, fever, rectal pain, and rash. Less common or rare effects include serious organ-specific events reported in post-marketing surveillance.

Systemic and Serious Safety Concerns

The safety profile encompasses multiple organ systems. The Nervous System may present effects such as headache and dizziness. Adverse reactions affecting the Renal and Urinary System—including the development of nephrolithiasis (kidney stones) and reports of interstitial nephritis or renal failure—are a documented concern. The Cardiovascular System has rarely been associated with pericarditis or myocarditis as part of a hypersensitivity reaction.

A recognized serious adverse reaction is the Mesalamine-Induced Acute Intolerance Syndrome. Symptoms, which may mimic a severe flare of the underlying condition (including acute abdominal pain, cramping, and bloody diarrhea), are reported at the start of treatment and require prompt recognition.

Safety Considerations for Specific Populations

Regulatory documents emphasize that renal function should be evaluated before starting therapy and monitored periodically throughout treatment, particularly in patients with pre-existing renal impairment. Caution is also advised in patients with pre-existing hepatic disease, and adequate hydration is required during therapy to mitigate the risk of kidney stone formation. The rectal suspension formulation is formally contraindicated in individuals with known sensitivity to sulfites.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Rowasa (mesalamine rectal formulations) should be treated as a potentially serious medical event requiring immediate attention. Because mesalamine is an aminosalicylate, acute overexposure may lead to systemic clinical manifestations consistent with salicylate toxicity, which include symptoms such as tinnitus, headache, confusion, drowsiness, and hyperventilation. Severe overdose may result in life-threatening outcomes, including pulmonary oedema or severe acid-base disturbances.

When to Seek Immediate Medical Help

Individuals experiencing a suspected acute overdosage or any severe, unexplained symptoms must seek immediate medical evaluation. The regulatory label mandates prompt discontinuation of the product if the Mesalamine-Induced Acute Intolerance Syndrome is suspected, presenting with acute abdominal pain, bloody diarrhea, fever, and rash. Immediate evaluation is also required if there are signs of hypersensitivity reactions involving internal organs, such as the heart or liver.

Overdose Management

There is no specific antidote documented for mesalamine overdosage. Management is symptomatic and supportive, and may involve conventional therapy for salicylate toxicity, including measures to correct dehydration and electrolyte imbalance. Due to the drug's known preclinical toxicity profile, renal function evaluation is a critical component of monitoring in overdosage scenarios, as the kidney is documented as a principal target organ for mesalamine toxicity.

Therapeutic Uses of Rowasa

What Rowasa Treats: Main Uses and Benefits

The therapeutic role of Rowasa (Mesalamine rectal formulations) involves delivering localized supportive care to the lower bowel. The medication is commonly used across conditions presenting with acute, episodic manifestations of inflammation, making the drug available to the affected area where inflammation is present.

Managing Active Distal Ulcerative Colitis Flares

Rowasa is generally applied in addressing active mild-to-moderate ulcerative colitis that is anatomically confined to the distal segments of the large intestine, including ulcerative proctitis and proctosigmoiditis. Applied in clinical settings that involve acute or unstable symptom patterns, this therapy is relevant for easing symptoms related to inflammatory or irritative states and supports the process of achieving remission.

Easing Symptoms of Rectal Passage Distress

The medication assists with managing symptom clusters that may become intense or disruptive to daily functioning, specifically those linked to active rectal inflammation. It helps address pronounced symptoms such as rectal bleeding, excessive mucus discharge, and the painful, persistent urge to empty the bowels (tenesmus). This supportive therapeutic benefit may assist patients in coping more steadily with difficult episodes, contributing to the reduction of localized discomfort and urgency.

Sustaining Long-Term Symptom Control

For patients with chronic proctitis, the rectal suppository is commonly used to maintain a symptom-free state over time. Used over an extended period, this may assist in maintaining stability when symptoms are more noticeable. Applied in scenarios where additional management of discomfort is required, this long-term use supports the patient during difficult episodes by easing distress and assists with maintaining functional stability.

Quick Fact: Relief for Tenesmus

This focused therapeutic approach is commonly used to help with managing tenesmus, which is the distressing, inflammation-driven symptom of feeling an urgent need to defecate without successful bowel emptying.

Eligibility and Restrictions for Use

Who Can and Cannot Use Rowasa? — Official Regulatory Information

The eligibility profile for Rowasa (mesalamine rectal suspension) is defined by regulatory guidelines, primarily focusing on patient age, existing health conditions, and known allergies.

Populations for Whom Use is Contraindicated

Rowasa is contraindicated (must not be used) in patients with known or suspected hypersensitivity to the following substances:

Salicylates (e.g., aspirin).
Aminosalicylates (including mesalamine/5-ASA).
Sulfites, due to the presence of potassium metabisulfite in the rectal suspension enema.
Any other component of the medication.

Age-Related Eligibility and Condition-Based Rules

Category	Regulatory Status & Rule
Approved Age Group	Indicated for use in Adults only.
Pediatric Population	Safety and efficacy have not been established in children and adolescents.
Geriatric Population	Use is permitted, but caution is advised due to the likelihood of decreased organ function; monitoring of blood cell counts is recommended.
Renal Impairment	Requires evaluation of renal function before starting and periodically during therapy; discontinuation is required if renal function deteriorates.
Hepatic Impairment	Requires evaluation of risks and benefits due to reports of hepatic failure in patients with pre-existing liver disease.

Pregnancy and Lactation Status

Pregnancy: Human data are insufficient to inform a drug-associated risk. Use requires evaluation of the potential risk to the fetus against the mother's clinical need.
Lactation (Breastfeeding): Mesalamine and its metabolite are present in human milk; the decision to use requires balancing benefits against the potential for infant adverse effects (limited reports of diarrhea exist).

Connection to the overall eligibility profile: The regulatory documentation restricts Rowasa use to the adult population and mandates absolute prohibition for those with specific hypersensitivities. Furthermore, use is conditional in patients with pre-existing organ damage, requiring function monitoring as a strict requirement for continued administration.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile for Rowasa (mesalamine rectal formulations) is primarily structured around pharmacodynamic risks, which involve additive toxicity when co-administered with specific medicinal products. Regulatory documents provide specific cautions regarding drug-drug combinations and diagnostic test interference.

Interaction Type	Interacting Agent	Official Regulatory Statement
Additive Organ Toxicity	Nephrotoxic Agents (including NSAIDs)	Co-administration is associated with an increased risk of nephrotoxicity (adverse effects on renal function).
Additive Systemic Toxicity	Azathioprine or 6-Mercaptopurine (6-MP)	Co-administration is associated with an increased risk of myelotoxicity, potentially leading to blood disorders (blood dyscrasias).

Procedural and Population Constraints

The drug's metabolite, N-acetyl-5-aminosalicylic acid (N-Ac-5-ASA), may cause spuriously elevated test results when specific laboratory methods, such as liquid chromatography with electrochemical detection, are used to measure urinary normetanephrine.

Regarding specific populations, the documented risk of nephrotoxicity from co-administration with Nephrotoxic Agents or NSAIDs may be a greater concern for patients with pre-existing renal impairment or a history of renal disease.

No mandatory timing rules, contraindicated drug-drug combinations, or interactions with food, alcohol, or supplements are explicitly documented in the official regulatory prescribing information for Rowasa.

Mechanism of Action

The mechanism of Mesalamine (5-ASA) is primarily localized to the rectal and distal colonic lining, employing multiple anti-inflammatory actions to modulate the heightened physiological response in the tissue.

Multi-Target Inhibition of Inflammatory Mediators

Rowasa's mechanism initiates by locally inhibiting key enzymes in the Arachidonic Acid Cascade, specifically Cyclooxygenase (COX) and Lipoxygenase (LOX), directly at the affected tissue. This enzymatic suppression reduces the synthesis of pro-inflammatory signals, such as Prostaglandins and Leukotrienes, which drive local vascular permeability changes and immune cell chemotaxis.

Modulation of Genetic Regulation and Immune Signaling

The drug concurrently engages nuclear pathways by acting as an agonist for the PPAR-gamma receptor and suppressing the activation of the NF-kappaB transcription factor. This dual regulatory action alters the genetic expression profile of local immune and epithelial cells, supporting a pathway that reduces sustained pro-inflammatory protein synthesis and influences tissue stabilization.

Protection from Oxidative Tissue Damage

Mesalamine also functions as a free radical scavenger and antioxidant within the intestinal mucosa. By directly neutralizing highly destructive Reactive Oxygen Species (ROS) produced during the inflammatory response, the drug helps minimize ongoing collateral damage to the cellular lining, preserving the tissue barrier and contributing to the overall modulation of local inflammatory response.

Dosage and Administration Information

Rowasa is a medication for localized rectal application, available as a rectal suspension (enema) and a rectal suppository. The dosing pattern is a fixed, once-daily application for a finite course of treatment.

Official Administration and Dosage

Administration is performed once a day, and is preferably done at bedtime to maximize the retention time of the medication in the distal bowel. The standard dose is one instillation of the 4 gram rectal suspension or one 1000 mg suppository.

The typical duration of treatment ranges from 3 to 6 weeks, after which the course may be discontinued based on the clinical context. If a dose is missed, it should be administered as soon as it is remembered, unless it is nearly time for the next scheduled dose; two doses are not used simultaneously to compensate for a missed one.

Procedural Instructions and Handling

Use of the rectal suspension requires the bottle to be shaken well immediately before application to ensure the dose is homogeneous. The enema is instructed to be retained for approximately eight hours, ideally overnight, while the suppository should be retained for at least one to three hours. An evaluation of kidney function is performed for patients starting mesalamine therapy. Furthermore, adequate fluid intake is maintained during the treatment course. The suppository form must not be cut or broken.

Recent Clinical Evidence

Research evidence / Overview of Studies for Rowasa

This section provides a structural overview of the clinical research conducted on Rowasa (mesalamine rectal forms), focusing on the types of studies performed, the patient groups studied, and the questions researchers aimed to answer, based on official and peer-reviewed sources.

Evidence for Use in Active Distal Ulcerative Colitis Flares

The clinical evaluation for studies focused on active inflammation in the rectum and lower colon (distal ulcerative colitis) mainly relies on randomized controlled trials (RCTs). These studies were designed to explore short-term symptom patterns over defined time intervals, typically lasting four to eight weeks. Researchers used established scoring systems to monitor changes in outcomes such as rectal bleeding and stool frequency, which are outcomes linked to inflammatory or irritative states. The study populations included adult patients with endoscopically confirmed inflammation categorized as mild or moderate severity.

Findings from this research, synthesized across multiple studies, describe patterns observed in the trials when the rectal mesalamine formulation was used compared to a placebo. This evidence contributes to understanding symptom patterns in the lower bowel during conditions characterized by fluctuating or episodic manifestations.

Evidence for Use in Maintaining Remission in Ulcerative Proctitis

Research for studies focused on achieving a stable, symptom-free state relies on long-term, double-blind RCTs. These studies were specifically designed to monitor outcomes over extended periods, commonly spanning 12 to 24 months. The primary outcome monitored was the time elapsed until the recurrence of symptoms (relapse). The research focused on populations of adult patients with ulcerative proctitis who had already achieved clinical stability before the study began.

Studies report how the absence of symptoms evolved in the observed populations over time compared to a placebo. Findings describe patterns associated with how remission was sustained in patients during conditions presenting with cycles of stability and flare-ups.

Research Gaps and Limitations

Key research gaps and limitations in the overall evidence landscape include:

Follow-up durations were limited in the acute treatment studies, focusing mainly on the initial weeks of use, leaving long-term outcomes not fully established.
The majority of the long-term maintenance data specifically focuses on the suppository formulation, limiting the direct information available for the rectal suspension (enema) in this role.
There is limited information specifically derived from research examining the rectal formulations in children or older adults, meaning certainty remains low in these specific populations.

Key Studies & References

A Comprehensive Review of Topical Therapies for Distal Ulcerative Colitis

Frequently Asked Questions (FAQ)

Common questions about Rowasa (FAQ)

Q: How quickly does Rowasa start working?

A: Studies and official information indicate that a typical course of Rowasa treatment lasts between three and six weeks. Initial patterns of change or symptom improvement were observed in studies across the typical treatment period, though individual responses may vary.

Q: Can Rowasa be used for conditions other than ulcerative colitis?

A: Official regulatory documents specify that Rowasa is indicated for the treatment of active mild-to-moderate distal ulcerative colitis, proctosigmoiditis, or proctitis in adults. It is not approved for conditions outside of this specific indication.

Q: What happens if I use Rowasa for longer than recommended?

A: Regulatory guidance indicates that the medication must be used only for the duration prescribed. The typical labeled duration is three to six weeks. The potential risks of using Rowasa beyond the prescribed course length are not fully established in the short-term acute treatment studies.

Q: Are there any long-term side effects associated with Rowasa?

A: Mesalamine products have been associated with reports of serious organ issues, including renal impairment (such as nephrolithiasis or renal failure) and hematologic disorders. The official prescribing information requires regular monitoring of kidney function throughout therapy.

Q: Can I stop using Rowasa suddenly?

A: It is important to complete the full course of treatment as prescribed by the clinician. Stopping the medication prematurely may lead to a flare-up or worsening of the underlying inflammatory condition, consistent with clinical trial observations.

Q: Is Rowasa the same as other mesalamine products?

A: Rowasa contains the same active ingredient, mesalamine (5-ASA), as other drugs in its class. However, Rowasa is formulated specifically for rectal delivery (enema or suppository) to target inflammation directly in the lower colon and rectum, unlike oral mesalamine products.

Q: What is the difference between Rowasa and balsalazide?

A: Both Rowasa and balsalazide are aminosalicylate drugs used to manage ulcerative colitis. Rowasa is a rectal suspension or suppository approved for adults, while balsalazide is a different chemical form that is taken orally and may be approved for use in certain pediatric populations.

Q: Does Rowasa affect the stomach or other parts of the digestive system?

A: Rowasa is primarily intended for local action in the rectum and lower colon with poor systemic absorption. Nevertheless, common side effects reported in clinical trials include gastrointestinal issues such as abdominal pain, nausea, and diarrhea.

Q: Can Rowasa cause changes in mood or sleep?

A: Official regulatory information for mesalamine rectal products lists headache as a common side effect. Less common reports of central nervous system effects such as anxiety have also been noted in some product information.

Q: Are there any common foods or drinks that interact with Rowasa?

A: Official regulatory prescribing information for Rowasa does not explicitly document any mandatory timing rules or contraindicated interactions with common foods, drinks, alcohol, or supplements.

Q: Does Rowasa contain sulfa or aspirin?

A: The active ingredient, mesalamine, is an aminosalicylate that is not considered a sulfa drug and does not contain a sulfa group. However, the rectal suspension contains sulfites, and Rowasa is contraindicated for individuals with known hypersensitivity to salicylates (like aspirin) or sulfites.

Q: Is Rowasa considered a steroid?

A: No, Rowasa is not a steroid. It belongs to a different pharmaceutical class known as aminosalicylates, which are non-steroidal anti-inflammatory agents.

Q: Why is Rowasa not intended for treatment of Crohn's disease?

A: Rowasa's official approval (indication) is specifically limited to the treatment of active mild-to-moderate distal ulcerative colitis and related inflammatory conditions in the rectum. Crohn's disease is not an officially labeled use for this medication.

Q: How does Rowasa help with rectal bleeding?

A: Rowasa's mechanism involves local anti-inflammatory action intended to reduce inflammation in the intestinal lining. This reduction of inflammation addresses the underlying cause of symptoms like rectal bleeding, consistent with the drug's labeled purpose.

Q: Is Rowasa safe to use during pregnancy?

A: Official information states that human data are currently insufficient to establish a definitive drug-associated risk for use during pregnancy. The regulatory framework dictates that use during pregnancy must involve a formal evaluation of the potential risk to the fetus against the clinical need of the mother.

Q: Is there a generic version of Rowasa available?

A: Yes, the active ingredient in Rowasa, mesalamine rectal suspension, is available from manufacturers as a generic medication.

Q: Does Rowasa help with joint pain or other systemic symptoms?

A: Rowasa is designed to be a localized therapy and is poorly absorbed into the systemic circulation. It is specifically intended to treat inflammation in the rectum and lower colon and is not labeled for systemic symptoms like joint pain.

How should Rowasa be stored and disposed of?

Storage and Disposal Requirements

Rowasa (mesalamine) Rectal Suspension Enema must be stored at Controlled Room Temperature, which is maintained between 20 to 25 C (68 to 77 F), with temporary excursions permitted to 15 to 30 C (59 to 86 F). The medication must be kept in its original container and stored out of reach of children.

Stability and Handling

Rowasa is supplied in foil-wrapped pouches. Once a foil-wrapped unit is opened, the enemas should be used promptly. Although a slight darkening of the suspension is possible and does not affect potency, any enema contents that have turned dark brown must be discarded.

Discarding Unused Product

Empty or unused disposable enema bottles and applicator tips should be disposed of safely and away from children and pets. General guidelines for unused medicines recommend mixing them with an undesirable substance, such as coffee grounds, placing the mixture in a sealed container, and then discarding it in household trash.

Rowasa